Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report)’s stock price fell 5.8% during trading on Wednesday . The company traded as low as $30.01 and last traded at $29.8960. 4,631,262 shares traded hands during mid-day trading, a decline of 82% from the average daily volume of 25,859,250 shares. The stock had previously closed at $31.75.
Key Headlines Impacting Hims & Hers Health
Here are the key news stories impacting Hims & Hers Health this week:
- Positive Sentiment: Truist raised its price target for Hims & Hers from $27 to $32 while maintaining a “hold” rating. Separate coverage highlighted a bullish outlook for weight-loss revenue and suggested GLP-1 customers remain engaged, supporting the company’s growth prospects. Truist price target report Bullish weight-loss revenue forecast
- Neutral Sentiment: The National Advertising Division issued a mixed decision in a dispute involving Hims & Hers’ hair-treatment advertising. It found support for one combination-efficacy message but recommended modifying or discontinuing other claims, creating some compliance and marketing uncertainty. NAD advertising decision
- Negative Sentiment: Visa reportedly placed Hims & Hers in its Acquirer Monitoring Program following a rise in credit-card billing disputes. The move could add penalty costs and intensify concerns about subscription billing, cancellations and pressure on margins. Visa monitoring program report
- Negative Sentiment: The company faces scrutiny from the FTC and state authorities over alleged health-data sharing with advertisers, deceptive billing practices and difficult subscription cancellations. Multiple law firms have also announced investigations into possible securities-law violations and potential breaches of fiduciary duty by the board. These announcements do not establish wrongdoing but increase litigation, regulatory and reputational risk. FTC and state scrutiny Board investigation
- Negative Sentiment: An analyst downgrade contributed to a gap lower, adding to investor caution after reports of payment disputes. Analyst downgrade report
Analyst Ratings Changes
HIMS has been the topic of a number of recent research reports. Citigroup dropped their price objective on shares of Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating on the stock in a research note on Tuesday, August 11th. Wall Street Zen upgraded Hims & Hers Health from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Bank of America boosted their target price on shares of Hims & Hers Health from $30.00 to $32.00 and gave the company a “neutral” rating in a report on Tuesday, August 11th. BTIG Research restated a “neutral” rating on shares of Hims & Hers Health in a research report on Tuesday, May 12th. Finally, UBS Group set a $23.00 price objective on shares of Hims & Hers Health in a research report on Friday, May 22nd. Four equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $32.50.
Hims & Hers Health Trading Down 6.0%
The company has a current ratio of 0.93, a quick ratio of 0.87 and a debt-to-equity ratio of 4.21. The stock has a 50 day moving average price of $32.39 and a 200 day moving average price of $26.23. The company has a market cap of $6.96 billion, a PE ratio of -47.46 and a beta of 2.40.
Hims & Hers Health (NYSE:HIMS – Get Free Report) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.32). Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The firm had revenue of $753.21 million for the quarter, compared to analysts’ expectations of $698.90 million. During the same period last year, the company posted $0.17 earnings per share. The business’s revenue for the quarter was up 38.2% compared to the same quarter last year. Sell-side analysts predict that Hims & Hers Health, Inc. will post -0.14 EPS for the current fiscal year.
Insider Transactions at Hims & Hers Health
In other news, CFO Oluyemi Okupe sold 55,383 shares of the business’s stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $35.09, for a total value of $1,943,389.47. Following the transaction, the chief financial officer directly owned 228,938 shares in the company, valued at $8,033,434.42. The trade was a 19.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Patrick Harrison Carroll sold 23,726 shares of the company’s stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $35.00, for a total transaction of $830,410.00. Following the transaction, the insider owned 181,861 shares of the company’s stock, valued at approximately $6,365,135. This represents a 11.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 186,769 shares of company stock worth $6,035,648. 11.76% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Hims & Hers Health
Several large investors have recently added to or reduced their stakes in the stock. Versant Capital Management Inc raised its holdings in Hims & Hers Health by 801.2% during the 2nd quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock valued at $26,000 after buying an additional 665 shares during the period. MassMutual Private Wealth & Trust FSB raised its stake in shares of Hims & Hers Health by 70.0% in the second quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock valued at $27,000 after acquiring an additional 319 shares during the period. Binnacle Investments Inc bought a new stake in shares of Hims & Hers Health in the 3rd quarter worth about $28,000. Bogart Wealth LLC lifted its holdings in shares of Hims & Hers Health by 235.8% in the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after acquiring an additional 632 shares during the last quarter. Finally, Geneos Wealth Management Inc. purchased a new position in shares of Hims & Hers Health during the 1st quarter worth about $30,000. 63.52% of the stock is owned by institutional investors.
Hims & Hers Health Company Profile
Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.
The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.
Featured Stories
- Five stocks we like better than Hims & Hers Health
- Looking Beyond NVIDIA? These 3 AI ETFs Are Beating the Market
- Palantir’s Kool-Aid Moment: The Math Behind Karp’s Forecast
- OpenAI’s Jalapeño Chip Could Change the AI Hardware Race
- Gold and Bitcoin Are Rebounding—2 ETFs Give Investors a Different Kind of Exposure
Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.
